The Optimisation & Developability program brings together leaders in computational design, machine learning, and biophysical profiling to build drug‑ready biologics from the outset. Talks will highlight scalable structure‑based modeling, ML‑driven lead optimization, and multi-objective property engineering across antibodies, multispecifics, and AOCs. A dedicated developability segment will focus on next-generation workflows, tackling functional complexity in challenging molecules, and embedding manufacturability considerations to ensure smooth progression from molecules to robust clinical products.